Impact of neoadjuvant chemotherapy on thrombus viability in patients with Wilms tumour and caval extension: systematic review with meta-analysis

Boam, TD, Gabriel, M, Shukla, R and Losty, PD ORCID: 0000-0003-0841-5879 (2021) Impact of neoadjuvant chemotherapy on thrombus viability in patients with Wilms tumour and caval extension: systematic review with meta-analysis. BJS OPEN, 5 (3). zrab020-.

Access the full-text of this item by clicking on the Open Access link.

Text
BJS Open Wilms PDL 2021 .docx - Author Accepted Manuscript
Download (151kB)

Official URL: http://dx.doi.org/10.1093/bjsopen/zrab020

Abstract

<h4>Background</h4>Inferior vena cava (IVC) tumour thrombus in children with Wilms tumour is typically managed with neoadjuvant chemotherapy with the intention of achieving thrombus regression in order to minimize the risks associated with complex vascular surgery.<h4>Methods</h4>A systematic review of Medline and Embase databases was undertaken to identify all eligible studies with reference to thrombus viability in Wilms tumour index cases with caval/cardiac extension. A meta-analysis of proportions was utilized for pooled thrombus viability data across studies. Logistic regression was used to analyse the relationship between thrombus viability and duration of chemotherapy.<h4>Results</h4>Thirty-five eligible observational studies and case reports met inclusion criteria describing a total of 236 patients with thrombus viability data. The pooled proportion of patients with viable tumour thrombus after neoadjuvant chemotherapy was 0.53 (0.43-0.63). Logistic regression analysis of 54 patients receiving either a standard (4-6 weeks) or extended (more than 6 weeks) course of neoadjuvant chemotherapy resulted in an odds ratio of 3.14 (95 per cent c.i. 0.97 to 10.16), P = 0.056, with extended course therapy trending towards viable tumour thrombus.<h4>Conclusion</h4>Preoperative chemotherapy is successful in achieving non-viability of caval and cardiac thrombi in around 50 per cent of children, without added benefit from extended cycles of neoadjuvant chemotherapy. Risks versus benefits of extirpative vascular surgery must be considered, therefore, for these high-risk patients.

Item Type:	Article
Uncontrolled Keywords:	Vena Cava, Inferior, Humans, Kidney Neoplasms, Thrombosis, Neoadjuvant Therapy, Retrospective Studies, Child, Wilms Tumor
Depositing User:	Symplectic Admin
Date Deposited:	11 Feb 2021 08:49
Last Modified:	09 Feb 2024 06:29
DOI:	10.1093/bjsopen/zrab020
Open Access URL:	https://doi.org/10.1093/bjsopen/zrab020
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3115459